Nuvectis Pharma registers Phase 1b trial of NXP900 plus lorlatinib in ALK+ NSCLCAug 25Trial updatelorlatinibNuvectis Pharma, Inc.
Nuvectis reports Q2 2026 results as ciprocopan wins first China approvalAug 4Quarterly updateNuvectis Pharma, Inc.
Nuvectis Pharma prices $100 million public stock offering at $20 per shareJun 30FinancingNuvectis Pharma, Inc.
Sign inSign in